138 results
8-K
LRMR
Larimar Therapeutics Inc
31 May 24
Submission of Matters to a Vote of Security Holders
4:07pm
, or their earlier death, resignation, or removal, as follows:
Name
Votes For
Votes Withheld
Broker Non-Votes
Jonathan Leff
Jeffrey W. Sherman, M.D
8-K
EX-99.2
LRMR
Larimar Therapeutics Inc
20 May 24
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
4:08pm
and frequent falling, and patients are eventually confined to a wheelchairLife expectancy of 30-50 years with an early death usually caused by heart
8-K
EX-99.2
LRMR
Larimar Therapeutics Inc
9 May 24
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
7:02am
falling, and patients are eventually confined to a wheelchairLife expectancy of 30-50 years with an early death usually caused by heart disease Affects
PRE 14A
LRMR
Larimar Therapeutics Inc
12 Apr 24
Preliminary proxy
6:06am
and qualified or appointed, or until their earlier death, resignation or removal. Directors are elected by a plurality of the votes cast by our stockholders … , or their earlier death, resignation, or removal. Each of the nominees has agreed to be named and to serve, and we expect each nominee to be able to serve
8-K
EX-99.2
3ak tu51j1gqu50i
11 Mar 24
Other Events
4:09pm
8-K
EX-99.3
ta5m34l szasv1ewby
11 Mar 24
Other Events
4:09pm
8-K
EX-1.1
l706b0 tjfn
16 Feb 24
Entry into a Material Definitive Agreement
4:06pm
424B5
94k1e5uk5nj92 mdkd
14 Feb 24
Prospectus supplement for primary offering
5:08pm
424B5
gw4hrkxyf6pbgv y60ip
13 Feb 24
Prospectus supplement for primary offering
4:46pm
8-K
EX-99.3
7o5p04qascs sy2j3k
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
EX-99.2
mwa9a2r
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
EX-99.2
ldmjx4y 5iu4alr296o
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am
8-K
EX-99.1
njruh7nybm7mlz 36l
14 Aug 23
Other Events
8:00am
8-K
EX-99.2
x4hb0xweqmh2j2
25 Jul 23
Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial’s 50 mg cohort expected in 1H 2024
7:02am
8-K
EX-99.1
ha4c8 148sl4acecl
1 Jun 23
June 2023 Larimar Therapeutics Corporate Presentation
4:06pm